Therapy Areas: Cardiovascular
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics
3 November 2021 - - US-based biotechnology company Moderna Inc. (NASDAQ: MRNA) and US-based genetic medicines company Metagenomi, Inc have entered into a strategic research and development collaboration focused on advancing new gene editing systems for in vivo human therapeutic applications, the companies said.

The collaboration will utilize Metagenomi's novel gene editing tools and leverage Moderna's mRNA platform, as well as lipid nanoparticle delivery technologies, with the goal of developing curative therapies for patients with serious genetic diseases.

Under the terms of the collaboration, Metagenomi and Moderna will advance a series of in vivo gene editing therapeutics against undisclosed targets.

Metagenomi said it will utilize its toolbox of gene editing systems in combination with Moderna's mRNA and LNP technologies, to deliver next-generation therapies for genetic diseases.

Metagenomi will receive an upfront cash payment and is eligible to receive certain target option exercise fees as well as development, regulatory and commercial milestone payments, plus tiered royalties on net sales of any products that are commercialized by Moderna.

Moderna has also agreed to make an equity investment in Metagenomi in the form of a convertible note.

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA, to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed.

Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.

Most recently, Moderna's capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.